The need for cytoprotection
- 31 December 1996
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 32, S2-S4
- https://doi.org/10.1016/s0959-8049(96)00329-2
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II studyBritish Journal of Cancer, 1995
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapyCancer, 1993
- Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients on Combination ChemotherapyJNCI Journal of the National Cancer Institute, 1993
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.Journal of Clinical Oncology, 1992
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumNew England Journal of Medicine, 1988
- Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamideBritish Journal of Cancer, 1980